Pontine Glioma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update

Pages: 649 Published: October 31, 2021 Report Code: GMDGDHC13140IDB

The pontine glioma pipeline market research report provides comprehensive information on the therapeutics under development for pontine glioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for pontine glioma and features dormant and discontinued projects.

What are the key targets in the pontine glioma pipeline market?

The key targets in the pontine glioma pipeline market are Cells Expressing CD276 Antigen, Cyclin Dependent Kinase, Cyclin Dependent Kinase, Histone Deacetylase, Programmed Cell Death Protein 1, Baculoviral IAP Repeat Containing Protein, Cells Expressing Wilms Tumor Protein, DNA, Epidermal Growth Factor Receptor, and Histone Deacetylase 1. Among them Cells Expressing CD276 Antigen has the highest number of pipeline products in the pontine glioma pipeline market.

Pontine glioma pipeline market, by targets

Pontine glioma pipeline market, by targets

For more target insights, download a free sample

What are the key MoA in the pontine glioma pipeline market?

The key MoA in the pontine glioma pipeline market are Cytotoxic To Cells Expressing CD276 Antigen, Cyclin Dependent Kinase 4 Inhibitor, Cyclin Dependent Kinase 6 Inhibitor, Histone Deacetylase Inhibitor, Programmed Cell Death Protein 1 Antagonist, Cytotoxic To Cells Expressing Wilms Tumor Protein, DNA Synthesis Inhibitor, Histone Deacetylase 1 Inhibitor, Histone Deacetylase 3 Inhibitor, and Serine/Threonine Protein Kinase mTOR Inhibitor. Cytotoxic To Cells Expressing CD276 Antigen has the highest number of pipeline products in the pontine glioma pipeline market.

Pontine glioma pipeline market, by MoA

Pontine glioma pipeline market, by MoA

For more MoA insights, download a free sample

What are the key RoA in the pontine glioma pipeline market?

The key RoA in the pontine glioma pipeline market are Oral, Intravenous, Intratumor, Subcutaneous, Intraperitoneal, Intrathecal, Parenteral, Intradermal, Intracerebral, Intralesional, Intraarterial, and Intravenous Drip. Oral has the highest number of pipeline products.

Pontine glioma pipeline market, by RoA

Pontine glioma pipeline market, by RoA

For more RoA insights, download a free sample

What are the key molecule types in the pontine glioma pipeline market?

The key molecule types in the pontine glioma pipeline market are Small Molecule, Cell Therapy, Monoclonal Antibody, Subunit Vaccine, Gene-Modified Cell Therapy, Monoclonal Antibody Conjugated, Oncolytic Virus, Antisense Oligonucleotide, Fusion Protein, Gene Therapy, Protein, and Synthetic Peptide. Small Molecule has the highest number of pipeline products in the pontine glioma pipeline market.

Pontine glioma pipeline market, by molecule type

Pontine glioma pipeline market, by molecule type

For more molecule type insights, download a free sample

Which are the key companies in the pontine glioma pipeline market?

The key companies in the pontine glioma pipeline market are Bristol-Myers Squibb Co, Midatech Pharma Plc, Novartis AG, Y-mAbs Therapeutics Inc, A. Menarini Industrie Farmaceutiche Riunite Srl, Accendatech Co Ltd, Adastra Pharmaceuticals Inc, Apexigen Inc, Bayer AG, Bexion Pharmaceuticals LLC, and BioMarin Pharmaceutical Inc. Bristol-Myers Squibb Co has the highest number of products in the pontine glioma pipeline market.

Pontine glioma pipeline market, by companies

Pontine glioma pipeline market, by companies

To know more about key companies, download a free sample

Market report scope

Key targets Cells Expressing CD276 Antigen, Cyclin Dependent Kinase, Cyclin Dependent Kinase, Histone Deacetylase, Programmed Cell Death Protein 1, Baculoviral IAP Repeat Containing Protein, Cells Expressing Wilms Tumor Protein, DNA, Epidermal Growth Factor Receptor, and Histone Deacetylase 1
Key MoA Cytotoxic To Cells Expressing CD276 Antigen, Cyclin Dependent Kinase 4 Inhibitor, Cyclin Dependent Kinase 6 Inhibitor, Histone Deacetylase Inhibitor, Programmed Cell Death Protein 1 Antagonist, Cytotoxic To Cells Expressing Wilms Tumor Protein, DNA Synthesis Inhibitor, Histone Deacetylase 1 Inhibitor, Histone Deacetylase 3 Inhibitor, and Serine/Threonine Protein Kinase mTOR Inhibitor
Key RoA Oral, Intravenous, Intratumor, Subcutaneous, Intraperitoneal, Intrathecal, Parenteral, Intradermal, Intracerebral, Intralesional, Intraarterial, and Intravenous Drip
Key Molecule Type Small Molecule, Cell Therapy, Monoclonal Antibody, Subunit Vaccine, Gene-Modified Cell Therapy, Monoclonal Antibody Conjugated, Oncolytic Virus, Antisense Oligonucleotide, Fusion Protein, Gene Therapy, Protein, and Synthetic Peptide
Key Companies Bristol-Myers Squibb Co, Midatech Pharma Plc, Novartis AG, Y-mAbs Therapeutics Inc, A. Menarini Industrie Farmaceutiche Riunite Srl, Accendatech Co Ltd, Adastra Pharmaceuticals Inc, Apexigen Inc, Bayer AG, Bexion Pharmaceuticals LLC, and BioMarin Pharmaceutical Inc

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pontine Glioma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Pontine Glioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pontine Glioma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pontine Glioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pontine Glioma (Oncology)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pontine Glioma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pontine Glioma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Players

  • A. Menarini Industrie Farmaceutiche Riunite Srl

    Accendatech Co Ltd

    Adastra Pharmaceuticals Inc

    Apexigen Inc

    Bayer AG

    Bexion Pharmaceuticals LLC

    BioMarin Pharmaceutical Inc

    Bionaut Labs Inc

    Boehringer Ingelheim International GmbH

    Bristol-Myers Squibb Co

    CDG Therapeutics Inc

    Chimerix Inc

    Curis Inc

    DNAtrix Inc

    Eisai Co Ltd

    Eli Lilly and Co

    EnGeneIC Ltd

    F. Hoffmann-La Roche Ltd

    Gate2Brain SL

    Incuron LLC

    InnoMab Pte Ltd

    Kazia Therapeutics Ltd

    Kintara Therapeutics Inc

    Lumos Pharma Inc

    M4K Pharma Inc

    Mana Therapeutics Inc

    Medicenna Therapeutics Corp

    Midatech Pharma Plc

    MimiVax LLC

    Moleculin Biotech Inc

    Novartis AG

    Oblato Inc

    OncoRx Pharmaceuticals Inc

    Oncotelic Inc

    Ono Pharmaceutical Co Ltd

    Pfizer Inc

    Plus Therapeutics Inc

    PTC Therapeutics Inc

    Regeneron Pharmaceuticals Inc

    Secura Bio Inc

    Shionogi & Co Ltd

    Sumitomo Dainippon Pharma Co Ltd

    TCR Cure Biopharma Technology Co Ltd

    Tmunity Therapeutics Inc

    Xcovery Holding Co LLC

    Y-mAbs Therapeutics Inc

    ZIOPHARM Oncology Inc

Table of Contents

Table of Contents

Introduction

Pontine Glioma – Overview

Pontine Glioma – Therapeutics Development

Pontine Glioma – Therapeutics Assessment

Pontine Glioma – Companies Involved in Therapeutics Development

Pontine Glioma – Drug Profiles

Pontine Glioma – Dormant Projects

Pontine Glioma – Discontinued Products

Pontine Glioma – Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Pontine Glioma, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Pontine Glioma – Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, 2021

Pontine Glioma – Pipeline by Accendatech Co Ltd, 2021

Pontine Glioma – Pipeline by Adastra Pharmaceuticals Inc, 2021

Pontine Glioma – Pipeline by Apexigen Inc, 2021

Pontine Glioma – Pipeline by Bayer AG, 2021

Pontine Glioma – Pipeline by Bexion Pharmaceuticals LLC, 2021

Pontine Glioma – Pipeline by BioMarin Pharmaceutical Inc, 2021

Pontine Glioma – Pipeline by Bionaut Labs Inc, 2021

Pontine Glioma – Pipeline by Boehringer Ingelheim International GmbH, 2021

Pontine Glioma – Pipeline by Bristol-Myers Squibb Co, 2021

Pontine Glioma – Pipeline by CDG Therapeutics Inc, 2021

Pontine Glioma – Pipeline by Chimerix Inc, 2021

Pontine Glioma – Pipeline by Curis Inc, 2021

Pontine Glioma – Pipeline by DNAtrix Inc, 2021

Pontine Glioma – Pipeline by Eisai Co Ltd, 2021

Pontine Glioma – Pipeline by Eli Lilly and Co, 2021

Pontine Glioma – Pipeline by EnGeneIC Ltd, 2021

Pontine Glioma – Pipeline by F. Hoffmann-La Roche Ltd, 2021

Pontine Glioma – Pipeline by Gate2Brain SL, 2021

Pontine Glioma – Pipeline by Incuron LLC, 2021

Pontine Glioma – Pipeline by InnoMab Pte Ltd, 2021

Pontine Glioma – Pipeline by Kazia Therapeutics Ltd, 2021

Pontine Glioma – Pipeline by Kintara Therapeutics Inc, 2021

Pontine Glioma – Pipeline by Lumos Pharma Inc, 2021

Pontine Glioma – Pipeline by M4K Pharma Inc, 2021

Pontine Glioma – Pipeline by Mana Therapeutics Inc, 2021

Pontine Glioma – Pipeline by Medicenna Therapeutics Corp, 2021

Pontine Glioma – Pipeline by Midatech Pharma Plc, 2021

Pontine Glioma – Pipeline by MimiVax LLC, 2021

Pontine Glioma – Pipeline by ZIOPHARM Oncology Inc, 2021

Pontine Glioma – Dormant Projects, 2021

Pontine Glioma – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Pontine Glioma, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

Frequently Asked Questions

$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.